Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences develops CRISPR genome-edited, allogeneic CAR-T cell therapies for hematologic malignancies. Company updates center on vispacabtagene regedleucel, or vispa-cel, an anti-CD19 CAR-T therapy being evaluated in B cell non-Hodgkin lymphoma and large B cell lymphoma, and CB-011, an anti-BCMA CAR-T therapy for relapsed or refractory multiple myeloma.
Recurring announcements include clinical and translational data from the ANTLER and CaMMouflage trials, FDA designations and trial-design interactions, financial results, research and development spending, cash resources, pipeline prioritization, and medical or investor conference participation.
Caribou Biosciences priced its upsized initial public offering (IPO) of 19,000,000 shares at $16.00 each, aiming for gross proceeds of $304 million. The shares will trade on Nasdaq under the symbol CRBU, beginning July 23, 2021, with the offering expected to close around July 27, 2021. Underwriters have a 30-day option to purchase an additional 2,850,000 shares. BofA Securities, Citigroup, and SVB Leerink are serving as joint book-running managers for the offering.